TR201909584T4 - İşlenmiş anti-IL-23p19 antikorların solüsyon formülasyonları. - Google Patents

İşlenmiş anti-IL-23p19 antikorların solüsyon formülasyonları. Download PDF

Info

Publication number
TR201909584T4
TR201909584T4 TR2019/09584T TR201909584T TR201909584T4 TR 201909584 T4 TR201909584 T4 TR 201909584T4 TR 2019/09584 T TR2019/09584 T TR 2019/09584T TR 201909584 T TR201909584 T TR 201909584T TR 201909584 T4 TR201909584 T4 TR 201909584T4
Authority
TR
Turkey
Prior art keywords
antibodies
solution formulations
engineered anti
formulations
engineered
Prior art date
Application number
TR2019/09584T
Other languages
English (en)
Inventor
S Kashi Ramesh
Badkar Aniket
Original Assignee
Merck Sharp & Dohme
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=50934859&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=TR201909584(T4) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Merck Sharp & Dohme filed Critical Merck Sharp & Dohme
Publication of TR201909584T4 publication Critical patent/TR201909584T4/tr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39591—Stabilisation, fragmentation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/515—Complete light chain, i.e. VL + CL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Abstract

Mevcut buluş, anti-insan interlökin-23 p19 (IL-23p19) antikoru hum13B8-b'nin yüksek konsantrasyonlu solüsyon formülasyonlarını ve bunların çeşitli rahatsızlıkların tedavi edilmesinde kullanımlarını sağlar.
TR2019/09584T 2012-12-13 2013-12-09 İşlenmiş anti-IL-23p19 antikorların solüsyon formülasyonları. TR201909584T4 (tr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201261737035P 2012-12-13 2012-12-13

Publications (1)

Publication Number Publication Date
TR201909584T4 true TR201909584T4 (tr) 2019-07-22

Family

ID=50934859

Family Applications (1)

Application Number Title Priority Date Filing Date
TR2019/09584T TR201909584T4 (tr) 2012-12-13 2013-12-09 İşlenmiş anti-IL-23p19 antikorların solüsyon formülasyonları.

Country Status (31)

Country Link
US (2) US20150329632A1 (tr)
EP (1) EP2931313B1 (tr)
JP (1) JP6266012B2 (tr)
KR (1) KR102004585B1 (tr)
CN (1) CN104870016B (tr)
AU (1) AU2013359767B2 (tr)
BR (1) BR112015013540B1 (tr)
CA (1) CA2894869C (tr)
CL (1) CL2015001608A1 (tr)
CY (1) CY1121895T1 (tr)
DK (1) DK2931313T3 (tr)
EA (1) EA034616B1 (tr)
ES (1) ES2732861T3 (tr)
HK (1) HK1215194A1 (tr)
HR (1) HRP20191137T1 (tr)
HU (1) HUE045668T2 (tr)
IL (3) IL278295B2 (tr)
LT (1) LT2931313T (tr)
MX (1) MX357936B (tr)
MY (1) MY187921A (tr)
NZ (1) NZ708443A (tr)
PE (1) PE20151524A1 (tr)
PH (1) PH12015501296B1 (tr)
PL (1) PL2931313T3 (tr)
PT (1) PT2931313T (tr)
RS (1) RS59057B1 (tr)
SI (1) SI2931313T1 (tr)
TR (1) TR201909584T4 (tr)
UA (1) UA117466C2 (tr)
WO (1) WO2014093203A1 (tr)
ZA (1) ZA201504408B (tr)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI705827B (zh) * 2014-11-07 2020-10-01 瑞士商諾華公司 治療眼部疾病之方法
JP7179717B2 (ja) * 2017-03-31 2022-11-29 Ｍｅｉｊｉ Ｓｅｉｋａファルマ株式会社 水性製剤及び注射器入り水性製剤、並びに、抗体タンパク脱凝集剤及び抗体タンパク脱凝集方法
JP2021515770A (ja) * 2018-03-05 2021-06-24 ヤンセン バイオテツク，インコーポレーテツド 抗ｉｌ−２３特異的抗体を用いたクローン病の治療方法
KR20210093976A (ko) * 2018-11-21 2021-07-28 리제너론 파아마슈티컬스, 인크. 고농도 단백질 제형
MA55033A (fr) 2019-02-18 2021-12-29 Lilly Co Eli Formulation d'anticorps thérapeutique
WO2020172293A1 (en) * 2019-02-20 2020-08-27 Amgen Inc. Methods of determining protein stability
JP2022534020A (ja) 2019-05-23 2022-07-27 ヤンセン バイオテツク，インコーポレーテツド Ｉｌ－２３及びｔｎｆアルファに対する抗体の併用療法による炎症性腸疾患の治療方法
US20210070852A1 (en) * 2019-09-09 2021-03-11 Boehringer Ingelheim International Gmbh Anti-IL-23p19 Antibody Formulations
EP4077378A1 (en) * 2019-12-20 2022-10-26 NovaRock Biotherapeutics, Ltd. Anti-interleukin-23 p19 antibodies and methods of use thereof
CN115605231A (zh) * 2020-05-13 2023-01-13 信达生物制药（苏州）有限公司（Cn） 包含抗IL-23p19抗体的制剂、其制备方法和用途

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU3873200A (en) 1999-03-11 2000-09-28 Schering Corporation Mammalian cytokines; related reagents and methods
MXPA02002684A (es) 1999-09-09 2002-07-30 Schering Corp Citocinas de mamifero; reactivos y metodos relacionados.
MXPA04000747A (es) 2001-07-25 2004-07-08 Protein Desing Labs Inc Formulacion farmaceutica liofilizada estable de anticuerpos igg.
PT1441589E (pt) * 2001-11-08 2012-08-13 Abbott Biotherapeutics Corp Formulação farmacêutica líquida estável de anticorpos igg
US7132100B2 (en) 2002-06-14 2006-11-07 Medimmune, Inc. Stabilized liquid anti-RSV antibody formulations
WO2004071517A2 (en) 2003-02-06 2004-08-26 Schering Corporation Uses of il-23 related reagents
ZA200506159B (en) 2003-02-10 2006-10-25 Elan Pharm Inc Immunoglobulin formulation and method of preparation thereof
AU2004219625B9 (en) 2003-03-10 2010-12-23 Merck Sharp & Dohme Corp. Uses of IL-23 agonists and antagonists; related reagents
BRPI0403964B8 (pt) * 2003-04-04 2021-05-25 Genentech Inc formulações líquidas estáveis, artigo manufaturado e uso dessas formulações para o tratamento de disfunção mediada por ige
ATE533502T1 (de) 2004-02-17 2011-12-15 Schering Corp Verfahren zur modulation der il-23-aktivität; relevante reagenzien
EP1755673B1 (en) 2004-04-12 2014-07-23 MedImmune, LLC Anti-il-9 antibody formulations and uses thereof
JO3000B1 (ar) * 2004-10-20 2016-09-05 Genentech Inc مركبات أجسام مضادة .
GT200600031A (es) 2005-01-28 2006-08-29 Formulacion anticuerpo anti a beta
JP2009501006A (ja) 2005-06-30 2009-01-15 セントカー・インコーポレーテツド 抗ｉｌ−２３抗体、組成物、方法および用途
PL1937721T3 (pl) 2005-08-25 2010-12-31 Lilly Co Eli Przeciwciała anty-IL23
EP1931710B1 (en) 2005-08-31 2017-01-18 Merck Sharp & Dohme Corp. Engineered anti-il-23 antibodies
HUE034269T2 (en) 2005-12-29 2018-02-28 Janssen Biotech Inc Human anti-IL-23 antibodies, preparations, methods and applications
WO2007147019A2 (en) 2006-06-13 2007-12-21 Zymogenetics, Inc. Il-17 and il-23 antagonists and methods of using the same
EP2094247B1 (en) 2006-10-20 2022-06-29 Amgen Inc. Stable polypeptide formulations
CL2008000058A1 (es) 2007-01-09 2008-05-23 Wyeth Corp Formulacion que comprende un anticuerpo anti-il13, un criprotector, y una solucion amortiguadora; composicion farmaceutica que la comprende; metodo para tratar un trastorno relacionado con il13; y formas farmaceuticas que la comprenden.
TWI426918B (zh) 2007-02-12 2014-02-21 Merck Sharp & Dohme Ｉｌ-２３拮抗劑於治療感染之用途
US20100111966A1 (en) 2007-02-23 2010-05-06 Schering Corporation Engineered anti-il-23p19 antibodies
CA2678749C (en) 2007-02-23 2018-03-13 Schering Corporation Engineered anti-il-23p19 antibodies
US20090208492A1 (en) * 2007-06-14 2009-08-20 Elan Pharmaceuticals, Inc. Lyophilized Immunoglobulin Formulations and Methods of Preparation
US20090181027A1 (en) 2007-09-28 2009-07-16 Paul Dal Monte Anti-IL-12/23p40 Antibodies, Epitopes, Formulations, Compositions, Methods and Uses
AR068723A1 (es) 2007-10-05 2009-12-02 Glaxo Group Ltd Proteina que se une a antigenos que se une a il-23 humana y sus usos
KR101247418B1 (ko) 2007-12-21 2013-03-25 에프. 호프만-라 로슈 아게 항체 제형
CA2726087A1 (en) * 2008-06-03 2009-12-10 Tariq Ghayur Dual variable domain immunoglobulins and uses thereof
CA2734919C (en) * 2008-08-27 2016-08-16 Schering Corporation Lyophilized formulations of engineered anti-il-23p19 antibodies
BRPI0917888A2 (pt) * 2008-09-19 2014-02-25 Pfizer Formulação de anticorpo líquida estável
WO2010062896A1 (en) * 2008-11-28 2010-06-03 Abbott Laboratories Stable antibody compositions and methods for stabilizing same
US20110158987A1 (en) * 2009-12-29 2011-06-30 F. Hoffmann-Laroche Ag Novel antibody formulation
CN103429264A (zh) * 2011-03-31 2013-12-04 默沙东公司 针对人程序性死亡受体pd-1的抗体的稳定制剂和有关的治疗
EP3412310B1 (en) * 2012-03-07 2022-09-07 Cadila Healthcare Limited Pharmaceutical formulations of tnf-alpha antibodies

Also Published As

Publication number Publication date
UA117466C2 (uk) 2018-08-10
EP2931313A1 (en) 2015-10-21
KR102004585B1 (ko) 2019-07-26
PH12015501296A1 (en) 2015-08-24
PE20151524A1 (es) 2015-11-06
AU2013359767B2 (en) 2018-04-05
AU2013359767A1 (en) 2015-07-23
EP2931313A4 (en) 2016-08-03
NZ708443A (en) 2018-05-25
CY1121895T1 (el) 2020-10-14
CL2015001608A1 (es) 2015-10-30
JP6266012B2 (ja) 2018-01-24
IL239150B (en) 2020-11-30
HUE045668T2 (hu) 2020-01-28
LT2931313T (lt) 2019-09-25
IL307581A (en) 2023-12-01
MY187921A (en) 2021-10-28
SI2931313T1 (sl) 2019-09-30
CN104870016B (zh) 2018-05-08
CA2894869C (en) 2021-06-15
CN104870016A (zh) 2015-08-26
IL278295B2 (en) 2024-03-01
IL239150A0 (en) 2015-07-30
EA034616B1 (ru) 2020-02-27
BR112015013540B1 (pt) 2021-04-27
ES2732861T3 (es) 2019-11-26
EA201591133A1 (ru) 2015-10-30
DK2931313T3 (da) 2019-07-15
PL2931313T3 (pl) 2019-10-31
MX2015007213A (es) 2016-08-03
CA2894869A1 (en) 2014-06-19
KR20150092763A (ko) 2015-08-13
HK1215194A1 (zh) 2016-08-19
PH12015501296B1 (en) 2015-08-24
JP2016505572A (ja) 2016-02-25
US20210188964A1 (en) 2021-06-24
ZA201504408B (en) 2017-09-27
IL278295B1 (en) 2023-11-01
MX357936B (es) 2018-07-31
RS59057B1 (sr) 2019-08-30
PT2931313T (pt) 2019-07-10
WO2014093203A1 (en) 2014-06-19
HRP20191137T1 (hr) 2019-09-20
BR112015013540A2 (pt) 2017-11-14
EP2931313B1 (en) 2019-05-08
BR112015013540A8 (pt) 2018-04-17
IL278295A (tr) 2020-12-31
US20150329632A1 (en) 2015-11-19

Similar Documents

Publication Publication Date Title
TR201909584T4 (tr) İşlenmiş anti-IL-23p19 antikorların solüsyon formülasyonları.
CY1123079T1 (el) Τροποποιημενα πολυπεπτιδια γiα ικριωματα διειδικων αντισωματων
CL2016002816A1 (es) Anticuerpos anti-cd 134 (ox40) y usos de los mismos (divisional de sol. n° 631-14).
EA201590388A1 (ru) Способы лечения таупатии
MX2013009362A (es) Anticuerpo contra el csf-1r.
TN2013000378A1 (en) Anti - sclerostin antibody crystals and formulations thereof
CL2017002283A1 (es) Formulaciones de anticuerpos y métodos (divisional de solicitud n°1081-2014)
EA201400875A1 (ru) Антитела к cd47 и способы их применения
MX356337B (es) Anticuerpos contra csf-1r humano y sus usos.
NZ707086A (en) Anti-cd40 antibodies and methods of use
EA201390933A1 (ru) Антитела против мезотелина и иммуноконъюгаты
MX2019013670A (es) Formulaciones de anticuerpos y proteinas.
EA201390145A1 (ru) Конъюгаты, частицы, композиции и связанные с ними способы
MX2014012978A (es) Regiones de anticuerpo modificado y sus usos.
EA201201016A1 (ru) Антидоты антикоагулянтов
SG194701A1 (en) Anti-cd40 antibodies and methods of use
EA201300819A1 (ru) Молекулы антител, которые связываются с il-17a и il-17f
EA201592203A1 (ru) Способы лечения таупатии
CY1123519T1 (el) Ανθρωπινα μονοκλωνικα αντισωματα εξουδετερωσης il-ß
EA201400447A1 (ru) АНТИТЕЛА К CD1d
EA201301090A1 (ru) Антидоты антикоагулянтов
MX2014014381A (es) Anticuerpos de anti-teofilina y metodos de uso.
GT201300058A (es) Composiciones de anticuerpos anti-vegfr-3
TN2013000068A1 (en) Anti-vegfr-3 antibody compositions